It is important to treat both elevated intraocular pressure (IOP) and the underlying cause of the disease when managing NVG.[4] Vascular endothelial growth factor (VEGF) is the main causative agent of neovascularization.[5,6] Retinal ischemia has been shown to upregulate VEGF expression, which triggers an angiogenic signaling cascade that promotes neovascularization development in the iris and anterior chamber angle.[2,5–9] Therefore, anti-VEGF treatment is anticipated to play an important role in NVG treatment. This evidence concerns the gene VEGFA and retinal ischemia.